https://scholars.lib.ntu.edu.tw/handle/123456789/628974
標題: | Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial | 作者: | Chmielecki, Juliann Mok, Tony Wu, Yi-Long Han, Ji-Youn Ahn, Myung-Ju Ramalingam, Suresh S John, Thomas Okamoto, Isamu CHIH-HSIN YANG Shepherd, Frances A Bulusu, Krishna C Laus, Gianluca Collins, Barbara Barrett, J Carl Hartmaier, Ryan J Papadimitrakopoulou, Vassiliki |
公開日期: | 27-二月-2023 | 卷: | 14 | 期: | 1 | 來源出版物: | Nature communications | 摘要: | Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M resistance mutations. This analysis evaluates acquired resistance mechanisms to second-line osimertinib (n = 78) in patients with EGFR T790M advanced non-small cell lung cancer (NSCLC) from AURA3 (NCT02151981), a randomized phase 3 study comparing osimertinib with chemotherapy. Plasma samples collected at baseline and disease progression/treatment discontinuation are analyzed using next-generation sequencing. Half (50%) of patients have undetectable plasma EGFR T790M at disease progression and/or treatment discontinuation. Fifteen patients (19%) have >1 resistance-related genomic alteration; MET amplification (14/78, 18%) and EGFR C797X mutation (14/78, 18%). |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/628974 | ISSN: | 2041-1723 | DOI: | 10.1038/s41467-023-35962-x |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。